Biodexa Pharmaceuticals (BDRX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Biodexa Pharmaceuticals has successfully passed resolutions at its General Meeting to reduce the nominal value per ordinary share, without affecting the number of shares outstanding. This move comes as the company continues to focus on developing innovative treatments for diseases with unmet medical needs, including its lead programs eRapa, tolimidone, and MTX110. Biodexa’s advancements in drug delivery technologies support its ambitious pipeline, potentially boosting investor interest in its growth prospects.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
